Table 2.
Multivariable analysis for HLA-MSD HCT vs haploidentical HCT, 2013-2017
| Covariate | No. | HR | 95% Confidence interval | P |
|---|---|---|---|---|
| OS | ||||
| Main effect | ||||
| Haploidentical HCT | 393 | Reference | ||
| MSD HCT | 1627 | 1.13 | 0.94-1.36 | .18 |
| Remission status | ||||
| CR1 | 1571 | Reference | ||
| CR2+ | 449 | 1.86 | 1.58-2.19 | <.001 |
| Age (y) | <.001 | |||
| 18-29 | 572 | Reference | ||
| 30-39 | 367 | 0.97 | 0.77-1.22 | .78 |
| 40-49 | 432 | 1.30 | 1.05-1.60 | .02 |
| 50-59 | 417 | 1.49 | 1.21-1.85 | <.001 |
| 60-69 | 232 | 2.07 | 1.63-2.63 | <.001 |
| Donor/recipient sex match | ||||
| Other than F/M | 1523 | Reference | ||
| F/M | 497 | 1.29 | 1.10-1.51 | .002 |
| Ph-BCR-ABL1 status | .007 | |||
| Negative | 932 | Reference | ||
| Positive | 714 | 0.78 | 0.66-0.92 | .003 |
| T-cell-ALL/unspecified subtype | 374 | 1.02 | 0.84-1.24 | .83 |
| Donor/recipient CMV serostatus | .02 | |||
| +/+ | 1065 | Reference | ||
| +/− | 175 | 0.81 | 0.62-1.05 | .11 |
| −/+ | 370 | 0.76 | 0.62-0.93 | .007 |
| −/− | 378 | 0.84 | 0.69-1.01 | .07 |
| LFS | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MSD HCT | 1583 | 1.03 | 0.88-1.22 | .71 |
| Disease status | ||||
| CR1 | 1528 | Reference | ||
| CR2+ | 436 | 1.93 | 1.67-2.23 | <.001 |
| Conditioning regimen | ||||
| MAC-TBI | 1116 | Reference | ||
| MAC-chemotherapy | 376 | 1.35 | 1.15-1.60 | <.001 |
| RIC/NMA | 470 | 1.50 | 1.28-1.76 | <.001 |
| NRM | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MSD HCT | 1583 | 1.06 | 0.81-1.41 | .66 |
| Remission status | ||||
| CR1 | 1528 | Reference | ||
| CR2+ | 436 | 1.52 | 1.17-1.98 | .002 |
| Age (y) | <.001 | |||
| 18-29 | 553 | Reference | ||
| 30-39 | 353 | 0.66 | 0.44-0.99 | .04 |
| 40-49 | 422 | 1.19 | 0.86-1.65 | .28 |
| 50-59 | 411 | 1.59 | 1.17-2.16 | .003 |
| 60-69 | 225 | 2.10 | 1.49-2.96 | <.001 |
| Donor/recipient sex match | ||||
| Other than F/M | 1479 | Reference | ||
| F/M | 485 | 1.54 | 1.22-1.94 | <.001 |
| Relapse | ||||
| Main effect | ||||
| Haploidentical HCT | 381 | Reference | ||
| MSD HCT | 1583 | 0.99 | 0.81-1.21 | .93 |
| Remission status | ||||
| CR1 | 1528 | Reference | ||
| CR2+ | 436 | 2.25 | 1.89-2.68 | <.001 |
| Conditioning regimen | ||||
| MAC-TBI | 1116 | Reference | ||
| MAC-chemotherapy | 376 | 1.40 | 1.14-1.72 | .001 |
| RIC/NMA | 470 | 1.53 | 1.26-1.87 | <.001 |
| aGVHD, grade 2-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| MSD HCT | 1545 | 0.92 | 0.77-1.11 | .40 |
| aGVHD, grade 3-4 | ||||
| Main effect | ||||
| Haploidentical HCT | 376 | Reference | ||
| MSD HCT | 1545 | 1.09 | 0.79-1.50 | .59 |
| cGVHD | ||||
| MSD vs haploidentical HCT for donor/recipient sex match, other | 1.37 | 1.12-1.69 | .003 | |
| MSD vs haploidentical HCT for donor/recipient sex match, F/M | 2.59 | 1.68-3.99 | <.001 | |
| Age (y) | .002 | |||
| 18-29 | 563 | Reference | ||
| 30-39 | 361 | 1.13 | 0.93-1.37 | .24 |
| 40-49 | 428 | 1.37 | 1.14-1.64 | <.001 |
| 50-59 | 413 | 1.17 | 0.95-1.43 | .14 |
| 60-69 | 228 | 1.57 | 1.21-2.03 | <.001 |
| Race/ethnicity | ||||
| White Hispanic | 333 | Reference | ||
| White non-Hispanic | 1006 | 0.75 | 0.63-0.89 | .001 |
| Black | 132 | 0.93 | 0.70-1.23 | .61 |
| Asian | 130 | 0.79 | 0.59-1.07 | .13 |
| Other/not specified | 392 | 0.66 | 0.53-0.82 | <.001 |
| Donor/recipient sex match | ||||
| Other than F/M | 1501 | Reference | ||
| F/M | 492 | 0.73 | 0.47-1.14 | .17 |
| Conditioning regimen | ||||
| MAC-TBI | 1132 | Reference | ||
| MAC-chemotherapy | 380 | 0.94 | 0.79-1.11 | .46 |
| RIC/NMA | 478 | 0.74 | 0.61-0.90 | .002 |
F, female; M, male.